220 related articles for article (PubMed ID: 16354309)
1. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
2. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
3. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF; Reck M
Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
[TBL] [Abstract][Full Text] [Related]
4. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
5. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
6. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
7. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY; Gow CH; Yang PC
N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
[No Abstract] [Full Text] [Related]
8. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
9. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
10. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract][Full Text] [Related]
11. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Amler LC; Goddard AD; Hillan KJ
Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
13. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
14. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Lai RS; Xie L; Shen LS; He YM; Zhu CL
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
[No Abstract] [Full Text] [Related]
15. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Myerson JS; Iqbal SA; O'Brien ME; Popat S
Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
17. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Irmer D; Funk JO; Blaukat A
Oncogene; 2007 Aug; 26(39):5693-701. PubMed ID: 17353898
[TBL] [Abstract][Full Text] [Related]
18. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
19. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
[TBL] [Abstract][Full Text] [Related]
20. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
